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Abstract
Vein graft failure occurs between 1 and 6 months after implantation due to obstructive intimal hyperplasia, related in part
to implantation injury. The cell-specific and temporal response of the transcriptome to vein graft implantation injury was
determined by transcriptional profiling of laser capture microdissected endothelial cells (EC) and medial smooth muscle
cells (SMC) from canine vein grafts, 2 hours (H) to 30 days (D) following surgery. Our results demonstrate a robust genomic
response beginning at 2 H, peaking at 12–24 H, declining by 7 D, and resolving by 30 D. Gene ontology and pathway
analyses of differentially expressed genes indicated that implantation injury affects inflammatory and immune responses,
apoptosis, mitosis, and extracellular matrix reorganization in both cell types. Through backpropagation an integrated
network was built, starting with genes differentially expressed at 30 D, followed by adding upstream interactive genes from
each prior time-point. This identified significant enrichment of IL-6, IL-8, NF-kB, dendritic cell maturation, glucocorticoid
receptor, and Triggering Receptor Expressed on Myeloid Cells (TREM-1) signaling, as well as PPARa activation pathways in
graft EC and SMC. Interactive network-based analyses identified IL-6, IL-8, IL-1a, and Insulin Receptor (INSR) as focus hub
genes within these pathways. Real-time PCR was used for the validation of two of these genes: IL-6 and IL-8, in addition to
Collagen 11A1 (COL11A1), a cornerstone of the backpropagation. In conclusion, these results establish causality
relationships clarifying the pathogenesis of vein graft implantation injury, and identifying novel targets for its prevention.
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Introduction
Surgical bypass grafting using autologous vein conduits is the
cornerstone therapy for coronary and peripheral arterial occlusive
disease. About 250,000 coronary artery bypass grafts (CABG) and
about 80,000 lower extremity vein graft implantations are
performed each year with an average cost of 44 billion dollars
[1–3]. More than 50% of CABG fail within 10 years, and 30–50%
of lower extremity vein grafts fail within 5 years from surgery [4].
Vein bypass graft failure is classified into three distinct phases:
early (less than 30 days), mid-term (3 to 24 months) and late
(greater than 2 years) [5]. Mid-term failure due to intimal
hyperplasia (IH) causing stenosis and ultimately occlusion is by
far the most common cause (.70%) of vein graft failure [6]. These
numbers beg better understanding of the molecular basis of these
lesions, in order to define targeted therapies that would reduce
failure rate.
Although some pharmacological therapies such as Aspirin and
dipyridamole, as well as statins have shown modest benefit in
improving CABG outcome [7–10], there has been no correspond-
ing benefit for lower extremity vein grafts [11]. A more recent
mechanistically oriented clinical trial, Project of Ex-Vivo vein graft
Engineering via Transfection (PREVENT-III), employing ex vivo
treatment of lower extremity vein grafts with a decoy of cell cycle
transcription factor, E2F, during the surgical procedure was also
ineffective in improving outcome [12].
Trauma to the vein graft at the time of implantation and
subsequent exposure to a new environment of arterial hemody-
namics [13,14] are considered two major pathogenic factors
involved in delayed graft failure. In response to this implantation
injury the vein graft wall undergoes an obligatory remodeling,
which if exaggerated, may result in IH, stenosis, and thrombosis
[15–17].
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39123Using transcriptional profiling of canine vein bypass grafts, our
laboratory has already identified critical transcriptome responses
to implantation injury [18]. However, the findings of these
previous studies were limited by the unavailability of a canine
specific gene array, and the inability to examine the individual
contributions of endothelial (EC) and smooth muscle cell (SMC)
layers to the altered transcriptome.
The principal hypothesis of our present study is that implan-
tation injury causes temporal genetic changes in EC and SMC of
vein grafts, triggering a cascade of interrelated molecular events
causing vessel wall remodeling and IH. Accordingly, we performed
transcriptional profiling of EC and SMC after their retrieval by
laser capture microdissection (LCM) from canine vein grafts,
a clinically relevant large animal model, at time-points ranging
2 hours (H) to 30 days (D) following the surgery. Backpropagation
analysis of transcriptional profile helped in ascribing the time
dependent genomic alterations to a specific vessel layer/cell type,
and in identifying most significantly affected pathways, as well as
gene-interaction focus hubs critically involved in implantation
injury. This allowed us to establish a vein graft implantation injury
signature, and to identify causality relationships that clarify its
pathogenesis, laying the foundation for strategies to prevent or
treat it.
Results
Purity of EC and SMC isolated by LCM
Purity of EC and medial SMC retrieved by laser capture
microdissection (LCM) from control veins and vein grafts was
determined by Q-RT-PCR using the cell-specific markers, Platelet
Endothelial Cell Adhesion Molecule-1 (PECAM-1/CD31) for EC
and Myosin Heavy Chain II (MHCII) for SMC. Gene expression
of CD31 was lower in control SMC as compared to control EC
(range of RQ=0.00960.004 to 0.260.2), and in graft SMC as
compared to graft EC (range of RQ=0.0660.009 to 0.2460.019)
at all time-points, suggesting that there was negligible contamina-
tion of SMC with EC (Figure S1A). Similarly, MHCII expression
was lower in control EC as compared to control SMC (range of
RQ=0.2260.05 to 0.460.1), and in graft EC as compared to
graft SMC (range of RQ=0.1660.07 to 0.460.14) at all time-
points, suggesting that there was negligible contamination of EC
with SMC (Figure S1B). Altogether, these results indicate that our
LCM samples were enriched by 80–99% for SMC, and by 60–
80% for EC.
Vein graft immunostaining for CD3 and CD18 showed almost
no positive cells on vascular graft sections retrieved at 12 and 24
H, while few CD3 and some CD18 positive cells were noted within
vein grafts media at 7 D, and adventitia at 30 D (Figure S2A &
S2B). Accordingly, transcriptional changes observed in vein graft
LCM samples were mostly representative of EC or SMC
transcriptomes.
Microarray quality control
The array data was determined to be of high quality as assessed
by the scaling factor, average background, percent present calls,
and 39-59 RNA ratio. In addition, dChip software for outlier
analysis did not identify any outlier array using the default criteria.
Implantation injury leads to time-dependent qualitative
and quantitative changes in the transcriptome of graft
EC and SMC
Principal Component Analysis (PCA) of pre-processed micro-
array data demonstrated that samples separated on the basis of
graft vs. control along Principal Component 1 (PC1), which
accounts for 25.8% of the variance; and on the basis of cell type
(EC vs. SMC) along PC2, which accounts for 14.3% of the
variance (Figure 1). This demonstrates that transcriptional
differences were greater between grafts and controls as compared
to transcriptional differences between cell types. Transcription
profiles of graft EC and SMC clustered temporally, and followed
a counter clockwise pattern, with 12 and 24 H graft samples being
most distant, and 7 and 30 D graft samples being less distant from
their corresponding controls (Figure 1). Unsupervised hierarchical
clustering depicted more transcriptional differences between
control vs. graft than between cell types at 12 H, 24 H and 7 D.
Clustering also depicted less transcriptional differences between
control vs. graft than between cell types at 2 H and 30 D consistent
with PCA results (Figure 1, & Figure S3). This suggests that injury
at the time of implantation triggers a potent acute response,
manifesting in early robust qualitative and quantitative changes in
gene transcription that resolves over time. Transcription profiles of
control EC and SMC clustered by cell type regardless of time-
points.
Characterization of the vein graft acute and sustained
genetic response to implantation injury
Using a bioconductor package [19,20] for statistical linear
model of microarray data, (LIMMA), we determined that a total of
3,651 EC genes and 4,299 SMC genes were differentially
expressed at the five time-points. All these genes achieved a false
discovery rate (FDR) adjusted p-value ,0.05, and an absolute fold
change between control and graft veins $2. To focus on
evolutionarily conserved transcripts, canine transcripts were
mapped to human orthologues, as determined by Affymetrix
array comparison database. A summary of the differentially
expressed genes at each time-point in EC and SMC is provided in
Table 1.
In both EC and SMC, the number of differentially expressed
genes peaked at 12 H through 7 D, and substantially decreased by
30 D. Interestingly, at 2 H, a considerably higher number of genes
were differentially expressed in EC as compared to SMC (229 vs.
28), likely reflecting EC being the first physical target of
implantation injury. The most robust response was noted between
12 H and 7 D, with differentially expressed genes ranging 608 to
2,657. In contrast, only 45 (,1%) and 22 (0.5%) genes were
differentially expressed at 30 D in EC and SMC, respectively.
Those included, components of the extra cellular matrix such as
major collagens and integrins, both indicators of healing. Re-
markably, at 12 H, 43% of differentially expressed genes (up and
down-regulated) were common in graft EC and SMC. Those
genes were mainly inflammatory and immune-regulated genes,
which indicated the central role of acute inflammatory processes in
driving vascular remodeling, associated with implantation injury.
Details of EC’s and SMC’s unique and shared up- and down-
regulated genes at all time-points are provided in Figures S4A &
S4B, and Table S2. Top differentially expressed genes from all
time-points, based on absolute fold-change, are listed in Table 2.
Additionally, we performed time-series analysis, using the
improved empirical ‘bayes’ approach, which considers correlations
within samples and between time-points. We identified 1,850
(3,748 probes) and 1,851 (3,750 probes) significantly modified
genes in graft EC and SMC, respectively, at p-value ,0.01. From
these genes, 1,525 EC genes (82% of 1,850) were identified, by
both time-series and individual time-point analyses (Figure 2A).
Using K-means clustering, we partitioned these 1,525 genes into 8
clusters with different expression patterns (Figure S5A), and
performed gene ontology (GO) enrichment analysis on each
cluster (Figure 2A). Clusters represent a range of expression
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multiple time-points. Cluster I consisted of acute response genes
linked to injury response that peaked at 2 H. Clusters II–IV
consisted of immune and inflammatory response genes that peaked
at 12 and 24 H. Cluster V consisted of genes linked to mitosis and
antigen processing and presentation, peaking at 7 D. Cluster VI
consisted of genes primarily involved in immune responses and
extracellular matrix organization that peaked at 7 and 30 D.
Clusters VII and VIII consisted of genes involved in muscle
contraction, neuronal differentiation and regulation of mitogen
activated protein kinase (MAPK) activity, that were down-
regulated at 12, 24 H and 7 D. The detail of genes involved in
each enriched GO Biological term is provided in Table S3A.
In SMC, we identified a total of 1,675 genes (90% of 1851), by
both time-series and individual time-point analyses (Figure 2B).
Similar to EC, we partitioned these 1,675 genes into 10 clusters
with different expression patterns (Figure S5B), and performed
GO enrichment analysis on each cluster (Figure 2B). Cluster I
consisted of genes involved in apoptosis and defense responses that
peaked at 2 and 12 H. Clusters II–IV consisted of inflammatory
response, leukocyte chemotaxis, nucleotide metabolism and
ribosome biogenesis genes, that peaked at 12 and 24 H. Clusters
V–VII consisted of genes involved in chromosomal segregation,
mitosis and integrin mediated signaling, peaking at 7 D. Cluster
VIII consisted of genes involved in integrin-mediated signaling
pathway and cell adhesion that peaked at 7 and 30 D. Cluster IX
primarily consisted of genes involved in muscle contraction,
vasculature and blood vessel development that were down-
regulated between 2 and 24 H. Cluster X primarily consisted of
genes involved in chemical homeostasis and cyclic nucleotide
metabolic processes that were down-regulated from 12 H to 7 D.
The detail of genes involved in each enriched GO Biological term
is provided in Table S3B.
Canonical Pathways Enrichment Analysis identifies
sequential biological processes driving vein graft
implantation injury
We performed pathways enrichment analysis (PEA), using
Ingenuity Pathway Analysis (IPA) tools, to determine the relation-
ship between temporal modification of gene expression in graft EC
and SMC and cellular biological outcomes. This analysis was
based on differentially expressed genes at individual time-points,
Figure 1. Principal Component Analysis (PCA) of the temporal expression data from control vein and vein graft. The preprocessed
transcriptional data from the control vein and vein graft endothelial cells (EC) as well as smooth muscle cells (SMC) is plotted along the top two
components from the PCA. The first component with highest variance (25.8%) is shown on the X-axis and second highest (14.6%) is displayed on the
Y-axis. On the basis of these components, the data can be differentiated in four major clusters i.e. control EC (dark red), control SMC (dark blue), graft
EC (light red) and graft SMC (light blue). Each cluster further consists of sub-clusters representing time dependent segregation. Each time-point is
represented with unique symbols (2 H =¤,1 2H=N,2 4H=&,7D=D and 30 D=*). In the plot, the distance between the samples is proportional
to correlation at the transcriptional profile level. For example, control and graft sample clusters from both EC and SMC have minimum correlation at
12 H (maximum distance) and maximum correlation at 30 D (minimum distance).
doi:10.1371/journal.pone.0039123.g001
Table 1. Differentially expressed genes in EC and SMC with valid gene symbols and human orthologous genes.
Cell Type EC SMC
2H 12H 24H 7D 30D 2H 12H 24H 7D 30D
Down-regulated Q32 Q956 Q535 Q387 Q4 Q1 Q1353 Q299 Q604 Q3
Up-regulated q197 q787 q605 q748 q41 q27 q1304 q309 q897 q19
Total 229 1743 1140 1135 45 28 2657 608 1501 22
doi:10.1371/journal.pone.0039123.t001
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Gene SYMBOL Graft EC Graft SMC
2H 12H 24H 7D 30D 2H 12H 24H 7D 30D
CDKN1A 1.79 1.60 1.65 1.44 2.41 2.77 2.33 1.34
CLEC5A 4.07 3.94 2.25 3.15 4.37 2.64 3.41 3.66
LAPTM5 2.51 3.44 4.17 4.71 3.39 3.35 2.64 3.23
TFPI2 5.19 5.70 6.44 4.66 6.46 7.57 7.14 5.79
LYZ 1.84 1.99 2.63 2.22 4.47 2.57 2.83 2.39
TMEM49 1.64 1.43 2.11 1.64 2.79 2.97 3.46 2.85
BIRC3 2.94 1.33 1.24 2.50 2.61 1.35 1.65 1.31
SERPINE1 4.07 2.41 2.32 2.43 3.14 2.63 3.58 2.76
SPP1 3.22 4.01 6.38 2.32 3.14 3.88 3.94
VCAN 2.01 3.07 2.92 2.87 3.18 2.60 3.60
ALOX5AP 2.90 3.36 3.09 3.19 2.96 2.30 2.27
IL18 2.01 3.79 4.21 2.40 3.46 3.20 1.91
EGR1 2.20 1.81 1.26 3.59 2.58 1.90 4.90
CLEC12A 3.63 2.50 2.79 3.42 4.44 1.73 1.13
SERPINE2 1.37 2.77 2.56 5.20 2.70 2.07 2.33
AIM1 1.66 1.67 2.50 2.43 1.72 1.83 1.97
ARHGAP9 1.94 3.58 3.52 1.83 3.18 2.40 3.19
CD44 3.77 1.54 2.51 1.62 1.67 1.44 1.09
FYB 3.84 4.17 4.01 3.50 4.28 3.03 1.98
GK 2.49 3.16 3.58 2.59 3.71 2.09 1.38
GMFG 2.37 2.50 2.79 2.04 2.57 2.52 2.49
IL-8 5.88 5.71 5.69 1.53 7.30 6.28 1.46
KMO 2.80 1.87 2.04 2.11 3.01 2.06 1.47
LCP1 2.25 3.57 4.38 4.43 3.47 2.38 2.56
MTHFD2 1.58 2.01 1.69 1.48 1.74 1.66 1.39
NCKAP1L 2.92 1.31 3.89 3.67 1.87 2.88 2.42
NRG1 2.22 2.81 2.96 2.45 2.00 1.68 1.22
PLAUR 2.50 3.65 2.73 1.57 3.73 4.98 2.92
FCGR1A 4.35 5.55 3.77 4.40 3.63 3.94 2.89
SLC22A1 22.10 23.04 22.65 21.29 22.83 23.38 22.28
ENPP2 22.86 23.52 21.76 23.41 22.49 22.63
BTC 22.28 23.68 23.27 22.58 23.14 23.07
HPSE2 23.06 22.81 22.45 23.30 22.56 21.38
CCDC88C 21.83 22.05 21.58 22.02 22.12 21.53
ADHFE1 22.01 21.70 21.15 21.70 21.52 21.11
AGPHD1 22.67 22.90 21.44 23.86 22.55 21.54
AKAP6 23.41 22.32 22.51 22.69 22.59 21.60
ALDH7A1 21.86 22.05 21.46 21.95 21.38 21.51
AMIGO2 23.87 23.43 23.58 24.95 23.69 23.31
ANGPTL1 24.23 24.03 22.57 23.67 22.87 21.88
ARMC4 22.24 22.32 21.99 22.42 22.43 21.39
CALCOCO1 22.71 22.68 21.61 23.30 23.49 21.69
CCDC3 21.77 22.19 23.22 21.43 21.72 21.60
CHN1 22.19 21.77 21.29 23.35 21.99 21.34
CKM 23.39 23.96 23.13 23.48 23.51 21.45
COCH 21.65 23.11 23.74 21.81 22.60 22.93
COL14A1 22.56 23.85 23.34 22.18 22.00 21.70
doi:10.1371/journal.pone.0039123.t002
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This PEA provided useful insight into the pathophysiology of
implantation injury
In EC, inflammatory and immune-related pathways were
enriched at multiple time-points. These included, interleukin-6
(IL-6) (2 and 24 H), interleukin-8 (IL-8) (2 and 24 H), innate and
adaptive immune cell signaling (2 and 24 H and 7 D), as well as
dendritic cell maturation (2 and 24 H and 7 and 30 D). In contrast,
some pathways were enriched at a single time-point, such as G2/
M DNA damage checkpoint regulation (7 D), and prothrombin
activation (30 D) (Figure 3A). Sequentially, enrichment of the IL-6,
IL-8 and glucocorticoid receptor pro-inflammatory signaling
started at 2 H, promoting chemotaxis of immune cells into the
vein graft wall. This was followed by enrichment of primary cell
mediated immune defense pathways involving macrophage and
monocyte mediated phagocytosis at 12 H, with associated
reduction of the acute phase response signals, and T cell and B
cell differentiation and development by 24 H. Subsequently,
inflammatory and immune-mediated damage to the vessel wall
triggered enrichment of cell cycle pathways (Mitotic role of Polo
kinases, G2/M DNA damage checkpoint regulation) that were
sustained up to 7D. This was followed by enrichment of cell repair
pathways such as actin/cytoskeleton signaling by 30 D (Figure 3A).
Table S4A provides detailed information of genes involved in each
significantly enriched pathway.
In SMC, no pathways were significantly enriched at 2 H,
reinforcing that EC are first to be impacted by, and respond to
implantation injury. However, the12 H time-point showed the
highest number of enriched pathways in SMC. Similar to EC,
these mostly included inflammatory and immune-related pathways
such as IL-10, IL-8, chemokine receptor type 4 (CXCR4), and
chemokine and macrophages signaling. As in EC, several path-
ways were enriched at multiple time-points, such as dendritic cell
maturation (12 H, 7 and 30 D), actin cytoskeleton signaling (12 H
and 7 D), and endothelin-1 signaling (12 and 24 H and 7 D)
(Figure 3B). In contrast, other pathways were enriched at a single
time-point, such as chemokine and CXCR4 signaling (12 H), and
Mitotic Roles of Polo-like Kinase (7 D). Table S4B provides
detailed information of genes involved in each significantly
enriched pathway.
In both EC and SMC, inflammatory and immune-related
pathways were enriched in an early and sustained manner,
highlighting the key role of inflammation in initiation and
progression of vein graft implantation injury. In contrast, other
pathways such as cell cycle regulation were enriched at later single
time-points, which implies a narrower therapeutic window for cell
cycle based therapies.
In addition to cell-specific PEA, we performed disease specific
pathways enrichment analysis using IPA, which includes a set of
manually curated pathways related to various disease processes
ranging from cancer to metabolic diseases. Several disease-specific
pathways that are relevant to the pathogenesis of vein graft
implantation injury were enriched at different time-points in both
cell types, including immune dysfunction related diseases such as
rheumatoid arthritis, atherosclerosis, and hepatic fibrosis
(Figures 4A & 4B). These results highlight the central role of
inflammation and immune dysfunction in the pathogenesis of
implantation injury. A list of genes involved in disease specific-
pathways is provided in Tables S5A & S5B.
Backpropagation based interactive network analysis
provides insight into key biological pathways linked to
implantation injury
To get a mechanistic insight into the pathophysiology of vein
graft implantation injury, we combined stage specific transcrip-
tional changes using interactive network analysis. Through
a backpropagation approach we generated a multilayered network
for each cell type. Accordingly, genes at a given time-point directly
interacted with partners at the immediate upstream level, thereby
connecting final lesions to initiating events (Figures 5A & 5B).
We then analyzed all genes encompassing all layers of the
backpropagation network, using Ingenuity Systems, in a way that
selected pathways that affected at least 10% of those genes. This
approach identified 6 and 5 dominant pathways in EC and SMC,
respectively (Figures S6A & S6B). Remarkably, 4 of these
pathways were common to both cell types, and included IL-6
signaling, nuclear factor kappa B (NF-kB) signaling, dendritic cell
maturation, and glucocorticoid receptor signaling. Interestingly,
most genes within the NFkB pathway were pro-inflammatory and
were upregulated at multiple time-points in graft EC and SMC,
indicating active and sustained inflammation. The most striking
observation within the GC pathway related to down-regulation of
the glucocorticoid receptor at multiple time-points, indicating loss
of regulatory anti-inflammatory pathways, thereby amplifying
inflammatory responses. IL-8 signaling and triggering receptor
expressed on myeloid cells 1 (TREM-1) signaling qualified as
dominant in EC specifically, while peroxisome proliferator-
activated receptor alpha (PPARa signaling, qualified as dominant
in SMC specifically.
To get further insight into time specific events, we also analyzed
each layer of the backpropagation network (Figures 5A & 5B). In
EC, the base 30 D network mainly comprised up-regulated genes
associated with cellular assembly and organization (Figure 5A).
Significantly interacting genes at 7 D, upstream of the 30 D base
layer were enriched for glucocorticoid receptor signaling, cell cycle
and IL-8 signaling. At 24 H, genes that significantly interacted
with the 7 D layer were enriched for TREM-1 signaling, liver X
receptor/retinoid X receptor (LXR-RXR) signaling, and dendritic
cell maturation. At 12 H, genes that significantly interacted with
the 24 H layer were enriched for TREM-1, NF-kB, and IL-6
signaling. At 2 H, genes that significantly interacted with the 12 H
layer were enriched for TREM-1, interleukin-15 (IL-15) and
granulocyte macrophage colony stimulating factor (GM-CSF)
signaling.
In SMC, the base 30 D network mainly comprised up-regulated
genes associated with Prothrombin activation, Cyclin Dependent
Kinase 5 (CDK5) signaling, and IL-6 signaling (Figure 5B).
Significantly interacting genes at 7 D, upstream of the 30 D base
layer were enriched for NF-kB activation, Platelet Derived
Growth Factor (PDGF) signaling, and RXR activation. At 24 H,
genes that significantly interacted with the 7 D layer were enriched
for glucocorticoid receptor, RXR, and PPAR signaling. At 12 H,
genes that significantly interacted with the 24 H layer were
enriched for TREM-1, PPARa, and NF-kB signaling. At 2 H,
Figure 2. Time series analysis of differentially expressed genes following vein graft implantation. A) EC, B) SMC: The columns
represent samples and the rows represent genes. Gene expression is shown with a pseudocolor scale (21 to 1) with red color denoting increase and
green color denoting decrease in gene expression. The heatmaps depict the differential gene expression patterns of endothelial cells (EC) and
smooth muscle cells (SMC) that are clustered using K means. The gene ontology categories enriched in each K means cluster are represented with
heatmaps. The detailed patterns of gene expression are provided for EC and SMC in Figures S3A & S3B respectively.
doi:10.1371/journal.pone.0039123.g002
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could not link them to a known canonical pathway. This indicated
that the integrated response of the SMC started later than that of
the EC. This time-specific analysis differs from the previous
integrated pathway analysis in that it offers a temporal appreci-
ation of the pathogenic events occurring during implantation
injury, while the other allows a global view of the network.
Remarkably, IL-6 and IL-8 signaling pathways spanned all EC
layers and 4 consecutive SMC layers, which qualifies them as key
to the pathogenesis of vein implantation injury. We propose the
following cascade of events, exemplifying the temporal dysregula-
tion of IL-6 and IL-8 signaling pathways. In EC, NF-kB up-
regulated at 2 H, is a direct transcriptional activator of IL-8, which
is up-regulated at 12 H [21]. In turn, vascular expression of IL-8 is
further enhanced by IL-1b and IL-1a that are up-regulated at 24H
[22,23]. IL-1a and b induce MMP2 expression, that is highly up-
regulated in the 7 D layers [24]. MMP2 drives the proteolytic
processing of collagen, which likely feeds back into up-regulation
of collagen genes, namely COL1A1 collagen 1A (COL1A),
collagen 1A2 (COL1A2), collagen 3A1 (COL3A1), and Collagen
Type I at 30 D.
In SMC, IL-1 a/b, that are up-regulated at 12 H increase the
transcription of IL-8 within the same layer (Figure 5B) [23]. This is
in turn amplified by increased expression of NF-kB, a direct
transcriptional activator of IL-8 [21]. Similarly, IL-1 a/b increase
the transcription of IL-6 at 7 D [23], which is also amplified by
Figure 3. Analysis of canonical pathways enrichment in vein grafts at different time-points. A) EC, B) SMC: Each panel denotes the
effect on canonical pathways at particular time-points after graft implantation. Each bar represents a pathway with significance of enrichment
determined using the Benjamini-Hochberg hypothesis corrected p-value (shown on primary X-axis). The directionality of the genes in each pathway is
depicted using a pseudocolor (red for up-regulated genes, green for down-regulated genes and clear for unmodified genes).
doi:10.1371/journal.pone.0039123.g003
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IL-6 [25]. Interestingly, IL-1 signaling is modulated by increased
expression at 24 H of IL-1 receptor II (IL1-R2), an antagonist of
IL-1 signaling [26]. Increased 7 D expression of IL-6 up-regulates
the proto-oncogenes Fos (as seen at 30 D) namely c-Fos, through
a direct STAT3-dependent-mechanism [27,28]. In turn c-Fos
transcriptionally represses Collagen Type I transcription by
binding an AP1 element on the Collagen type I promoter [29],
Figure 4. Analysis of disease-related pathways enrichment in vein grafts at different time-points. A) EC, B) SMC: Each panel denotes
the effect on disease pathways at particular time-points after graft implantation. Each bar represents a pathway with significance of enrichment
determined using the Benjamini-Hochberg hypothesis corrected p-value (shown on primary X-axis). The directionality of the genes in each pathway is
depicted using a pseudocolor (red for up-regulated genes, green for down-regulated genes and clear for unmodified genes).
doi:10.1371/journal.pone.0039123.g004
Figure 5. Backpropagation based interactive network analysis of the genes. A) EC, B) SMC: A hierarchical network of interactive genes
was developed consisting of differentially expressed genes from 30 D to 2 H. First level of the network was developed from the genes that are
significantly differentially expressed at the final time-point (30 D). Second level of the network was built using differentially expressed upstream
interactive genes at the prior time-point (7 D). This process was repeated until we reached the starting time-point of 2 H.
doi:10.1371/journal.pone.0039123.g005
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namely COL1A1 collagen 1A (COL1A), collagen 1A2 (COL1A2),
and even Collagen Type I at 30 D, similar to what seen in EC.
Identification of the signature network of vein graft
implantation injury
Having established the key interactive networks that are
involved in vein graft implantation injury in EC and SMC, we
sought to identify a single signature network that would best
qualify vein graft implantation injury. This signature network
consists of the 10 most interactive focus gene hubs common to EC
and SMC, as identified by the density of maximum neighborhood
component (DMNC). These genes comprised growth factor
receptors such as insulin receptor (INSR), and insulin like growth
factor receptor (IGFR), fibroblast growth factor receptor 2
(FGFR2), that were significantly down-regulated, several pro-
inflammatory cytokines namely IL-6, IL-8, IL-15 and IL-1A, that
were very significantly up-regulated, and signaling molecules such
as the serine threonine kinase, the Protein Kinase C beta
(PRKCB) that was significantly up-regulated, while the alpha
isoform, PRKCA was moderately down-regulated (Figure 6).
Importantly, IL-8 and IL-6 were the most up-regulated focus gene
hubs at all time-points, as depicted in the histograms in Figure 6.
To our knowledge, this is the first systematically defined signature
network described for vein graft implantation injury. We propose
that it could be used for diagnostic, prognostic and therapeutic
purposes.
Quantitative validation of vein graft implantation injury
focus hub genes IL-6 and IL-8
To validate the most differentially expressed focus hub genes
that were identified in the vein graft implantation injury signature
network, we analyzed the mRNA expression levels of IL-6 and IL-
8 in EC and SMC. IL-6 mRNA levels, analyzed by qRT-PCR
were increased by more than 1,000-fold in vein graft EC and SMC
at 2, 12, and 24 H, and 7 D, as compared to control vein EC and
SMC (Figure 7A). Similarly, IL-8 mRNA levels were increased by
more than 1,000-fold in vein graft EC and SMC, at 2, 12, and 24
H, 7 and 30 D, as compared to controls (Figure 7B). This indicated
that the vein graft was inundated with local pro-inflammatory
cytokines and chemokines, mainly produced by SMC, the most
abundant cell type in the vessel wall.
Downstream of IL-6 and IL-8, we analyzed Col11A1 mRNA
levels by qRT-PCR. Based on our backpropagation analysis,
Col11A1, a critical component of the extracellular matrix was one
of the most highly expressed genes later in the process of vein graft
implantation injury We were able to detect Col11A1 mRNA levels
by 24 H following vein graft implantation. However, ColA11A1
significantly up-regulated in vein graft EC and SMC starting at 7
D and persisted at 30 D after vein graft implantation as compared
to control vein EC and SMC (Figure 7C). These data confirm the
microarray findings and, in particular those focus hub genes that
were identified by interactive Systems Biology Analysis of focus
hub identification [30].
Discussion
Recently, major efforts have been undertaken to decrease the
rate of vein graft failure. One such endeavor was the PREVENT-
III trial aimed at ameliorating vein graft implantation injury by
delivering Edifoligide, an oligonucleotide decoy of E2F, a key
transcription factor involved in cell cycle regulation [12]. Although
this study failed to show any effect of E2F blockade, it did establish
the technology and demonstrate feasibility of exposure of the vein
graft to molecular therapies at the time of surgery, setting the stage
for future trials using alternative molecular targets.
Discoveries of novel therapies to prevent/treat vein graft
implantation injury have been hampered by the choice of
experimental animal models whose results often fail to translate
to the clinic, mostly due to inability to recapitulate human
disease
6. The canine model of autologous vein grafting is one of
few models that reproduce failure patterns and modes of healing in
clinical disease
7. In particular, these veins develop lesions of IH
within 30–90 days post-implantation. In the present study, we
used this canine model, and interrogated the transcriptome in
a temporal and cell type specific manner in order to better
understand the pathophysiology of vein graft implantation injury
and identify novel therapeutic strategies. Specifically, we used
Laser Capture Microdissection (LCM) to isolate endothelial and
medial layers for subsequent RNA extraction and transcription
profiling. Our study focused on early transcriptional events that we
believe to be key in dictating outcome. We did not interrogate
transcriptional changes of the neointima since this layer does not
develop in this model, or in clinical vein grafts before 30 D. In fact
IH is not significant in this model before 60–90 days. Future work
is focused on interrogating neointimal transcriptome in a long-
term model of canine vein graft failure
LCM yielded highly enriched EC and SMC samples allowing
the study of cell specific transcriptional changes. To our
knowledge, this is the first study using this approach. Unsupervised
PCA analysis of our gene chips demonstrated that graft EC and
SMC genes formed time dependent clusters with maximal
transcriptional changes appearing 12 to 24 H following implan-
tation, and diminishing over the 30 D time period. This tapered
response suggests that early intervention during the peri-operative
period may be sufficient to prevent/inhibit vein graft implantation
injury, and therefore limit the development of IH.
Supervised analysis of the transcriptional data depicted tempo-
ral modification of gene expression in EC and SMC. Interestingly,
some genes were modified over continuous time-points, whereas
others were either non-continuously modified or modified at
a single time-point, highlighting the importance of defining
optimal therapeutic windows for each given target. For example,
the proinflammatory chemokine IL-8 was up-regulated in EC
from 2 H up to 7 D, and in SMC from 12 H up to 7 D. This
pattern of up-regulation in both cell types could be ideal for
a targeted therapy aiming at interrupting early and mid
pathogenic inflammatory culprits involved in vein graft implan-
tation injury. In contrast, Col1A1 was up-regulated in both EC
and SMC only at 30 D, suggesting that this extracellular matrix
gene is likely a downstream participant in the pathogenesis of vein
graft implantation injury, and key to the vascular remodeling that
occurs in vein grafts. In addition this analysis also suggested that
graft EC might be the first responders to vein graft implantation
injury, as they obviate a change in their transcriptome as early as 2
H following implantation. In contrast, SMC do not show any
significant changes at this early time-point.
Gene ontology analysis on temporally, and differentially
expressed genes indicated that implantation injury affected
multiple ontological categories in both, EC and SMC. Enriched
GO clusters included apoptosis, inflammatory and immune
responses, mitosis and extracellular matrix reorganization. In
EC, apoptosis related genes were up-regulated and peaked at 2 H
following implantation confirming that rapid EC damage and loss
was critical in triggering the cascade of events leading to vein graft
injury [31]. In contrast, apoptosis related genes were up-regulated
and peaked in SMC at 12 H. The significance of increased
expression of pro-apoptotic genes in medial SMC is still unclear.
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promotes vascular damage and influences the phenotypic switch of
these cells from contractile to synthetic, therefore promoting IH.
On the other hand, increased apoptosis in neointimal SMC is
beneficial through reduction of established IH lesions [32,33].
Significantly heightened inflammatory responses detected in
both EC and SMC at 12 and 24 H suggested a central role for
inflammation in driving the injury response to vein graft
implantation. By 7 D, inflammation related genes tapered down
without returning to basal levels. In fact, inflammatory genes
spanned all time-points, were the most abundant of differentially
regulated genes, and were likely the key regulators of other
pathogenic processes. We propose that early targeting of key
inflammatory molecules could be an ideal approach to prevent
vein graft implantation injury. Previous in vivo studies have
demonstrated that blocking inflammatory responses do attenuate
IH [34,35]. Following heightened inflammation driven injury
response, we observed at later time-points, a significant up-
regulation of cell cycle related genes in both EC and SMC.
Recovery of the endothelium through cell proliferation is
beneficial to the healing process, while that of SMC may be
deleterious, as it promotes the development of a neointimal layer,
i.e. IH, the pathognomonic feature of mid-term vein graft failure.
Accordingly, therapies aimed at preventing/treating vein graft
failure using cell cycle inhibitors must spare EC, specifically target
SMC, and ideally be effective for at least a week following vein
graft implantation. Failure of the PREVENT trial may be related
to the therapeutic agent not fulfilling all of these criteria.
Figure 6. Signature network of vein graft implantation injury. The network represents top ten focal gene hubs identified using density of
maximum neighborhood component (DMNC) from backpropagation interaction network. The pseudocolor scale from violet to blue represents the
DMNC rank from 1–10. DMNC rank is a level of significance with smaller rank indicating increasing confidence of criticality for network functioning.
The bar graphs represent fold change for each focal gene hub in EC and SMC. Fold change of temporal data (2, 12 and 24 H, and 7 and 30 D) of EC
and SMC is depicted by black and grey colored bars respectively.
doi:10.1371/journal.pone.0039123.g006
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PLoS ONE | www.plosone.org 10 June 2012 | Volume 7 | Issue 6 | e39123Figure 7. Confirmation of change in gene expression of A) IL-6, B) IL-8 and C) Col11A1. A) Relative gene expression of IL-6 in graft EC and
graft SMC compared to control EC and control SMC respectively at 2, 12 and 24 H, and 7 and 30 D, B) Relative gene expression of IL-8 in graft EC and
graft SMC compared to control EC and control SMC respectively at 2, 12 and 24 H, and 7 and 30 D and C) Relative gene expression of Collagen11A1
(Col11A1) in graft EC and graft SMC compared to control EC and control SMC respectively at 24 H, and 7 and 30 D.
doi:10.1371/journal.pone.0039123.g007
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tion were significantly up-regulated by 30 D in both EC and SMC.
In particular, collagen genes were the most enriched class of ECM
components, consistent with the prominence of collagen as
a constituent of IH lesion [36]. Deposition of ECM is essential
for vein graft healing in response to injury under normal
circumstances, however in the special case of implantation injury
it can lead to stenosis and graft failure. Delayed therapies that
could tackle ECM deposition need to be optimized for reducing
pathogenic vascular remodeling while promoting positive vascular
remodeling [37].
In order to delineate a causality relationship between differen-
tially expressed genes after vein graft implantation, we analyzed
the data using a backpropagation approach that integrates
interactions between differentially expressed genes from the
different points, starting at the latest time-point; i.e. 30 D. This
means of analyzing the data offered a unique perspective of
identifying the upstream pathogenic effectors of vein graft
implantation injury, based on endpoint molecular signals involved
in lesion formation. Furthermore, this approach allowed us to
integrate into the same network genes derived from significantly
affected biological pathways and define interconnectivity between
these pathways. We identified 6 and 5 biological pathways that
were dominant in the backpropagation networks of EC and SMC,
respectively. Remarkably 4 of these pathways were common to
both cell types, three of which spanned all time-points, namely the
IL-8, IL-6 and dendritic cell maturation pathways. We surmise
that these 3 pathways are not only critical pathogenic effectors of
vein graft implantation injury, but also harbor promising
therapeutic targets. Within these pathways, the IL-8 gene itself
was up-regulated from 2 H to 7 D in EC and from 12 H to 7 D in
SMC, and the IL-6 gene was up-regulated from 12 H to 7 D in
both EC and SMC.
We propose that both IL-8 and IL-6 are central to the
pathogenesis of vein graft implantation injury. Specifically, IL-8 is
a pro-inflammatory CXC chemokine produced mainly by
neutrophils, monocytes and macrophages and also by EC and
vascular SMC in response to pro-inflammatory stimuli in a NF-kB
and activator protein-1 (AP-1) dependent manner [38–41]. IL-8
stimulates vascular endothelial growth factor (VEGF) expression
and the autocrine activation of VEGF Receptor 2 (VEGFR2) in
EC by activating NFkB thus promoting pro-inflammatory
angiogenesis, which has been associated with increased adventitial
neovascularization and IH [42–44]. IL-8 also leads to proliferation
and migration of vascular SMC thereby contributing to IH [45].
IL-6 is a pro-inflammatory cytokine mainly secreted by
activated macrophages and lymphocytes but also by EC and
SMC [46–48]. IL-6 is involved in immune regulation, hemato-
poiesis, inflammation and oncogenesis [49]. Although little is
known about the role of IL-6 in the pathophysiology of IH leading
to vein bypass graft failure, several studies have demonstrated that
IL-6 is pro-atherogenic through promoting EC dysfunction, SMC
proliferation and migration as well as recruitment and activation
of inflammatory cells [50–53].
Besides IL-8 and IL-6 several other genes from these pathways
have been associated with vascular remodeling and hence could
affect vein graft implantation injury. In particular, we noted
increased levels of transcriptional regulators such as NF-kB (P100/
P50), cytokines and cytokine receptors such as IL1A, IL1B and
IL1R2, regulators of extracellular matrix such as MMP2, CO-
L1A1 and collagen type 1; and decreased levels of regulators of cell
differentiation such as serum response factor (SRF) [54–56].
Based on the backpropagation networks, we also delineated the
top focus gene hubs that had the greatest interaction density in
both EC and SMC. The choice of these focus gene hubs was based
on the fact that they provide maximum stability to the back-
propagation network. In fact, targeting any of these genes as
modeled by their removal from the network offers the most
effective means to disrupt the network. Among those focus gene
hubs, IL-6, INSR and IGF1R are the genes showing the greatest
interaction density, closely followed by IL-8, IL-15 and FGFR2. In
fact, among those genes, IL-6 and IL-8 were the most up-regulated
genes, whereas INSR, IGF1R and FGFR2 were down-regulated.
These results further validate the key role of IL-6 and IL-8 as
pathogenic, and therefore as high profile therapeutic targets to
prevent vein graft implantation injury.
We have validated the up-regulation of IL-6 and IL-8 in graft
EC and SMC by qRT-PCR, and confirmed that IL-6 significantly
increases from 2 H and up to 7 D post-implantation while IL-8 is
up-regulated at all time-points including the 30 D time-point in
both cell types. Using qRT-PCR we also validated the up-
regulation of Coll11A1 at the later time-points, 7 and 30 D
suggesting a potential role for extracellular remodeling in driving
the healing process, while being the major component in lesion of
implantation injury. Current work in our laboratory is aimed at
developing local siRNA based therapies to concomitantly target
IL-6 and IL-8 secretion within the vein graft and evaluate how this
would impact vein graft implantation injury.
In conclusion, this study represents the first comprehensive
analysis of the genomic response to vein graft implantation injury
in a large animal model. LCM has made it possible to separately
define the genomic response of EC from that of medial SMC. Our
data indicates that a robust genomic response begins by 2 H, peaks
at 12–24 H, starts resolving by 7 D, and declines markedly by 30
D. Inflammatory pathways dominate the early response, followed
by modulators of cell cycling, and culminate in pathways involved
in extra-cellular matrix remodeling. By using a back-propagation
based systems biology analysis of the data, we were able to
establish a temporal and causative link between these pathways
that helped us identify the molecular signature of vein graft
implantation injury, including high intensity hubs. This informa-
tion provides a foundation for designing strategies for therapeutic
intervention to prevent or diminish implantation injury.
Materials and Methods
Canine Surgery
Unilateral reversed autologous cephalic vein to femoral artery
interposition graft surgery was performed, as described [18,57,58]
on 25-kg female mongrel dogs (n=3 animals per time-point).
Cephalic vein grafts, along with unperturbed contralateral
cephalic vein, which served as an experimental control, were
excised at the same time-points (2, 12 and 24 H and at 7 and 30
D). Surgical details are in Materials S1. All animal work protocol
(# 02606) was approved by Harvard Medical Area (HMA)
Standing Committee on Animals. The principal investigator on
the animal protocol is Dr. Mauricio Contreras. For detailed
surgical procedures please refer to Materials S1. Figure S7 depicts
representative histology images of control veins and vein grafts at
2, 12 and 24 H, and 7 and 30 D.
Laser Capture Microdissection (LCM) preparation and
RNA preparation
Six microns OCT embedded frozen cross-sections were
immediately placed on glass slides coated with LPC-membrane
(POL or PET Foil 1.35 mm, P.A.L.M. Microlaser Technologies,
Bernried, Germany), and stored at 280uC until microdissection.
LCM was performed using a P.A.L.M. microscope. We first
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circumference thereby isolating the endothelium, and repeated
this for the entire medial layer to capture medial SMC
(Figures S8A & S8B). We used 6–7 cross-sections per sample in
order to obtain sufficient amount of total RNA (minimum of 500
picograms) for amplification by the NuGEN WT-Ovation Pico
RNA Amplification System (Version 1.0). Before labeling and
hybridization to arrays, we combined layers from different cross-
sections of each sample for EC and SMC. RNA was subsequently
extracted from EC and medial SMC, amplified, fragmented and
biotinylated using NuGen FL-Ovation kit (NuGen, San Carlos,
CA). For details about RNA isolation, amplification, fragmenta-
tion and biotinylation from EC and SMC please refer to the
Materials S1.
Quantitative Real time PCR
Quantitative RT-PCR (qRT-PCR) was performed as described
to evaluate sample purity and validate target genes [59]. For
validation of tissue sample purity, EC (CD31) and SMC (Myosin
Heavy Chain II – MHCII) specific probes were used. For
validation of differentially expressed genes IL-6, IL-8 and
Collagen11A1 (Col11A1) specific primers were used. PCR was
performed in each cell-type from control vein and vein graft of
three different animals at each time-point. All primers were
synthesized by Integrated DNA Technologies (Coralville, IA).
Primer sequences are provided in Table S1.
Transcriptional profiling and data analysis
Transcriptional profiling was performed on canine genome 2.0
Affymetrix GeneChip, that contains .43,000 transcripts. Three
microarrays of both control veins and vein grafts per cell type and
per time-point were used. The three arrays were biological not
technical replicates, as they were obtained from 3 different animals
at each time. From each animal, we retrieved both control vein
and vein graft. After quality control analysis, scanned array images
were normalized by dChip [60]. Unsupervised analysis was
performed on normalized and preprocessed data using Principal
Component Analysis (PCA) and hierarchical clustering [61,62].
The Pearson Correlation test with complete-linkage method was
used to cluster control and graft samples from EC and SMC at
each time-point. Differentially expressed genes were identified
using a linear model from the ‘LIMMA’ package [63]. Transcripts
with absolute fold change $2 between control vein and vein graft
with a multiple test corrected p-value #0. 05 were considered
differentially expressed. Details of analyses are described in
Materials S1.
Time series analysis of gene expression data
To use full time and class information of the results, we also
analyzed the preprocessed data in a time series manner using the
Bayesian Estimation of Temporal Regulation (BETR) [64]. Details
of analyses are described in Materials S1.
Gene Ontology (GO) enrichment analysis
To identify the over-represented GO categories in differentially
expressed genes, we used the Biological Processes and Molecular
functions Enrichment Analysis available from the Database for
Annotation, Visualization and Integrated Discovery (DAVID)
[65]. Details of GO analyses are described in Materials S1.
Pathways and interactive network Systems Biology
analysis
The Ingenuity Pathway Analysis (IPA 7.0) (http//www.
ingenuity.com) was used to identify key interaction networks and
pathways significantly affected at different time-points in EC and
SMC. We developed a hierarchical network based on a back-
propagation approach starting from transcriptional changes at
30 days back to 2 hours (Figure S9). Using the 30 days base-layer
of differentially expressed genes, we build a network comprising
upstream interactive genes, using the network building and
growing utility in the IPA tool. Enriched pathways within this
hierarchical network were ranked using ratio of affected genes and
Fisher’s exact test. We then selected the top pathways that
included at least 10% of the genes from the hierarchical network,
and generated an integrated network using protein-protein,
protein-DNA, and protein-RNA known interactions. To identify
the key regulatory molecules within this integrated network, we
used density of maximum neighborhood component (DMNC)
algorithm [30]. Details of analyses are described in Materials S1.
Supporting Information
Materials S1 Text file for supplemental materials. A)
List of supplemental materials B) Supplemental Methods and, C)
Supplemental Material References.
(DOCX)
Figure S1 Q-RT-PCR based purity analysis of EC and
SMC isolated by LCM technique. A) mRNA expression of
CD31 in SMC compared to EC B) mRNA expression of MHCII
in EC compared to SMC. Results are expressed as mean 6 SEM
of 3 animals.
(TIF)
Figure S2 Immune cell contamination of vein grafts. A)
Representative immunohistochemistry image of CD3+ cell in-
filtration within control veins and vein grafts B) Representative
immunohistochemistry image of CD18+ cells within control veins
and vein grafts.
(TIF)
Figure S3 Unsupervised Pearson Correlation based
clusters of EC and SMC arrays at each time-point after
normalization and preprocessing of data. In most cases
biological replicates of each cell type have better correlation with
each other than with other cell types. Unsupervised hierarchical
clustering depicted more transcriptional differences between
control vs. graft than between cell types at 12 H, 24 H and 7 D.
Clustering also depicted less transcriptional differences between
control vs. graft than between cell types at 2 H and 30 D consistent
with PCA results (Figure 1).
(TIF)
Figure S4 Venn diagram analysis on significantly
differentially expressed genes at five different time-
points (2, 12 and 24 H, and 7 and 30 D) from graft vein
EC and SMC compared to control vein EC and SMC. A)
up-regulated genes B) down-regulated genes. Each eclipse
represents one time-point as indicated by zones of overlapping
expression. With each of these zones, overlapping circles represent
3 sets differentially expressed genes, that is, only EC, only SMC
and common to EC and SMC. Pink and Blue circles denote genes
differentially expressed in EC and SMC respectively. The list of
genes from each quadrant is provided in Table S2.
(TIF)
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PLoS ONE | www.plosone.org 13 June 2012 | Volume 7 | Issue 6 | e39123Figure S5 Expression patterns of temporally differen-
tially expressed genes identified using K means clusters.
A) EC clusters B) SMC clusters. Each cluster represents a set of
genes that depict similar expression pattern and are biologically
linked to a specific function. Genes are selected using time-series
analysis of vein graft and control veins. X-axis represents different
time-points and Y-axis represents gene expression on pseudoscale
from 23t o+3. For details on clusters please refer to Figure 2.
(TIF)
Figure S6 Top pathways comprising backpropagation
network. A) EC and B) SMC. This analysis identified 6 pathways
in EC and 5 pathways in SMC, affecting at least 10% of
backpropagation genes. The up- and down-regulated genes are
represented in red and green color respectively. The intensity of
the color representing each gene corresponds to the magnitude of
up- or down regulation of that gene in graft and control vein EC
and SMC. Size of the symbol representing the gene indicates the
number of connections that gene makes.
(TIF)
Figure S7 Representative histology images of control
vein and vein graft. H&E stained histological images at low (4X
or 10X) and high (40X) magnification of control vein and vein
graft at 2 H, 12 H, 24 H, 7 D and 30 D following implantation.
(TIF)
Figure S8 Representative Image of Laser Capture
Mircodissection (LCM). A) Medial and endothelial layers in
vein graft prior to LCM (Mag 40X), B) Isolated endothelial layer
after LCM (Mag 40X).
(TIF)
Figure S9 Workflow for generation of hierarchical back-
propagation network.
(TIF)
Table S1 List of Q-RT-PCR Primers.
(DOCX)
Table S2 List of unique differentially expressed genes
identified by comparing graft vs. control vein EC and
SMC at individual time points (2, 12, 24 H, and 7 and 30
D). The table represents fold change of significantly dysregulated
genes from each zone of the Venn diagram shown in Figure S2.
(PDF)
Table S3 Gene Ontology analysis of K-means clusters.
A) EC, and B) SMC: This analysis is performed using the
Database for Annotation, Visualization and Integrated Discovery
(DAVID) v6.7 and gene ontology categories with multiple tests
(Holm–Bonferroni method) corrected P value ,0.05 were
considered significant.
(PDF)
Table S4 List of genes from significantly enriched
canonical pathways in vein grafts at different time
points. A) EC, B) SMC. This analysis is performed using
Igenuity Pathway Analysis System and Pathways with multiple test
(Holm–Bonferroni method) corrected P value ,0.01 was consid-
ered significant.
(PDF)
Table S5 List of genes from significantly enriched
disease pathways in vein grafts at different time points.
A) EC, B) SMC. This analysis is performed using Ingenuity
Pathway Analysis System and Pathways with multiple test (Holm–
Bonferroni method) corrected P value ,0.01 was considered
significant.
(PDF)
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